Wells Fargo & Company has filed a preliminary pricing supplement for its new medium-term notes, indicating a strategic move to enhance its capital management. The notes, which are fixed-rate callable, will have a term of five years and are set to attract institutional investors.
This issuance is particularly significant as it underscores Wells Fargo's ongoing efforts to strengthen its funding options amidst a competitive landscape in the national commercial banking sector. The notes will pay interest semi-annually and are subject to the credit risk of Wells Fargo, meaning investors could face risks if the company defaults.
Background
Wells Fargo & Company, incorporated in Delaware, is a prominent player in the national commercial banking sector, classified under SIC code 6021. The company operates on the New York Stock Exchange under several tickers, including WFC, WFC-PY, and WFC-PL. The latest filing, dated November 13, 2026, is part of a series of recent filings that include multiple preliminary pricing supplements.
What the Filing Says
The filing, accession number 0001839882-26-056392, states that the notes are due on November 25, 2031, and are redeemable by Wells Fargo at 100% of their principal amount plus any accrued interest. The notes are priced at $1,000 each, with variations for eligible institutional investors.
Impact
This offering may affect various stakeholders, including institutional investors looking for fixed-income opportunities. It also reflects Wells Fargo's proactive approach in managing its capital structure, which may influence its competitive position within the banking industry.
What's Next
The filing does not say what happens next regarding the issuance process or any subsequent filings.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










